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Background: Evidence continues to mount concerning the importance of the enteric nervous system (ENS) in
controlling numerous intestinal functions in addition to motility and epithelial functions. Nevertheless, little is
known concerning the direct participation of the ENS in the inflammatory response of the gut during infectious or
inflammatory insults. In the present study we analyzed the ENS response to bacterial lipopolysaccharide, in
particular the production of a major proinflammatory cytokine, tumor necrosis factor-alpha (TNF-α).
Methods: TNF-α expression (measured by qPCR, quantitative Polymerase Chain Reaction) and production
(measured by ELISA) were measured in human longitudinal muscle-myenteric plexus (LMMP) and rat ENS primary
cultures (rENSpc). They were either treated or not treated with lipopolysaccharide (LPS) in the presence or not of
electrical field stimulation (EFS). Activation of extracellular signal-regulated kinase (ERK) and 5 ? -adenosine
monophosphate-activated protein kinase (AMPK) pathways was analyzed by immunocytochemistry and Western
blot analysis. Their implications were studied using specific inhibitors (U0126, mitogen-activated protein kinase
kinase, MEK, inhibitor and C compound, AMPK inhibitor). We also analyzed toll-like receptor 2 (TLR2) expression and
interleukin-6 (IL-6) production after LPS treatment simultaneously with EFS or TNF-α-neutralizing antibody.
Results: Treatment of human LMMP or rENSpc with LPS induced an increase in TNF-α production. Activation of the
ENS by EFS significantly inhibited TNF-α production. This regulation occurred at the transcriptional level. Signaling
analyses showed that LPS induced activation of ERK but not AMPK, which was constitutively activated in rENSpc
neurons. Both U0126 and C compound almost completely prevented LPS-induced TNF-α production. In the presence
of LPS, EFS inhibited the ERK and AMPK pathways. In addition, we demonstrated using TNF-α-neutralizing antibody that
LPS-induced TNF-α production increased TLR2 expression and reduced IL-6 production.
Conclusions: Our results show that LPS induced TNF-α production by enteric neurons through activation of the
canonical ERK pathway and also in an AMPK-dependent manner. ENS activation through the inhibition of these
pathways decreased TNF-α production, thereby modulating the inflammatory response induced by endotoxin.
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The enteric nervous system (ENS), composed of neurons
and enteric glial cells (EGC), is a central regulator of
gastrointestinal functions encompassing gut motility, elec-
trolyte transport and intestinal epithelial barrier (IEB)
functions [1]. Recently, the ENS has been recognized as a
major player in gut protection in response to pathogen or
inflammatory insult [2]. Conversely, the ENS is also af-
fected in disease, in particular in inflammatory bowel dis-
eases (IBD). Alterations in ENS functions and phenotype
(altered excitability and neuroplastic changes) occur in
IBD [3,4]. These changes are associated with gastrointes-
tinal (GI) dysfunctions such as altered motility, diarrhea
and even pain. The ENS could also be directly involved in
the inflammatory response to infectious or inflammatory
challenges. Indeed, in animal models of colitis, enteric
neuronal hyper- and hypoplasia was associated with in-
creased and reduced production of TNF-α, respectively
[5]. In addition, hypertrophy and hyperplasia of enteric
neurons has been reported in IBD [6]. However, the
mechanism responsible for neuronal modulation of the se-
verity of inflammation remains unknown. Being putatively
due to the modulation of neuroimmune interactions, it is
tempting to speculate that enteric neurons could directly
produce and regulate key cytokines involved in IBD.
During inflammation, the ENS responds to a wide
range of mediators, such as cytokines [7]. The ENS can
also respond to bacterial challenges such as lipopolysac-
charide, as it expresses a wide array of toll-like receptors
(TLRs). Enteric neurons express TLR4 [8,9]. TLR3 and
TLR7 are expressed in the myenteric and submucosal
plexi. TLR3, TLR4 and TLR7 are also expressed in EGC
[10-13]. The functional consequences of the activation
of TLRs by their ligands in enteric neurons remain
largely unknown. TLR2 was nevertheless shown to be
necessary for maintaining ENS integrity and protection
from colitis [14]. Stimulation of TLR4 in EGC induced
the release of nitric oxide [12]. However, the ability of
enteric neurons to respond to lipopolysaccharides (LPS)
and to synthesize cytokines such as TNF-α, as well as
the signaling pathways involved, remain unknown.
The overall aim of this study was to determine whe-
ther the ENS can directly respond to LPS by producing
the major proinflammatory cytokine TNF-α, and whe-
ther ENS activity can modulate this production.
Methods
Generation of enteric nervous system cultures
Rat ENS primary cultures (rENSpc) were performed as
previously described using the small intestines of E15
Sprague-Dawley rat embryos (Janvier Laboratories SA,
Le Genest-St-Isle, France) [15]. These procedures were
approved by the local Animal Care and Use Committee
(agreement E. 44011; INSERM, Nantes, France). Briefly,the small intestines of rat embryos were removed, diced
in Hank ? s Buffered Salt Solution (Sigma-Aldrich, Saint-
Louis, Missouri, United States) and collected in 5 mL of
Dulbecco? s modified Eagle? s medium (DMEM)-F12 (Gibco?,
Life Technologies, Carlsbad, California, United States)
(1:1) for digestion at 37?C for 15 minutes in 0.1% trypsin
(Sigma-Aldrich). The trypsin reaction was stopped by ad-
ding medium containing 10% fetal calf serum and then
treated by DNase I 0.01% (Sigma-Aldrich) for 10 minutes
at 37?C. After triturating with a 10 mL pipette, cells were
centrifuged at 750 rpm for 10 minutes. Cells were counted
and then seeded at a density of 2.4 ? 10 5 cells/cm−2 on
24-well plates previously coated with a solution of gelatin
(0.5%; Sigma-Aldrich) in sterile phosphate buffered saline.
After 24 hours, the medium was replaced with a serum-
free medium DMEM-F12 (1:1) containing 1% of N-2 sup-
plement (Life Technologies. Cultures were maintained for
14 days. Using this method, rENSpc is composed of well-
organized ganglia interconnected by interganglionic fiber
strands forming a network that lays on a smooth muscle
cells monolayer (smooth muscle actin or SMA positive
cells). Fluorescence-activated cell sorting (FACS) analysis,
aimed to reveal the cellular composition of the rENSpc,
revealed that enteric neurons and glial cells represent 5 to
6% and 20 to 40%, respectively, of cells present in culture
(personal observation). Half of the medium was replaced
every other day and the day before the experiment.
Enteric nervous system treatments
The rENSpc were treated with lipopolysaccharides (Esche-
richia coli and Salmonella typhosa; 1:1, Sigma-Aldrich) at
0.1 μg/ml for the indicated time, except for Figure 1A,
where different concentrations were tested. For the purpose
of establishing which pathways and receptors are implicated
in TNF-α and TLR2 regulation, U0126 (mitogen-activated
protein kinase kinase 1/2 or MEK1/2 inhibitor; 10 μM),
compound C (5? -adenosine monophosphate-activated pro-
tein kinase (AMPK) inhibitor; 10 μM) (Calbiochem, Merk
Millipore, Billerica, Massachusetts, United States) and
anti-rat TNF-α (1 and 10 μg/ml; eBiosciences, San Diego,
California, United States) were added 30 minutes prior to
the addition of LPS or ENS stimulation. Pam3CSK4
(TLR1/2 agonist; 100 ng/ml; Invivogen, San Diego,
California, United States), A438079 (selective P2X7
antagonist; 30 μM; Tocris Bioscience, Bristol, United
Kingdom), adenosine-5'-triphosphate (ATP) (100 μM)
and 2? (3? )-O-(4-benzoylbenzoyl) adenosine-5'-triphosphate
triethylammonium salt (BzATP) (selective P2X7 agonist;
100 μM; Sigma-Aldrich) were also used to treat ENS plus
or minus LPS.
Enteric nervous system activation
To study the effect of neuronal activity on cytokine se-
cretion, rENSpc were electrically stimulated in 24-well
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Figure 1 Enteric neurons produce TNF-α in response to LPS stimulation. (A) rENSpc were treated in a time- and dose-dependent manner
with LPS. Quantification of TNF-α secretion was measured by ELISA. Values represent the mean ? SEM of between three and seven independent
samples per condition (two-way ANOVA test followed by a Bonferroni post-hoc test; *P <0.05 as compared with the same time point without
LPS). (B) Representative images of TNF-α localization in the rENSpc (four independent samples). Immunocytochemical triple labeling of ENS
cultures were performed using anti-TNF-α, anti-S100β (glial marker) and anti-Tuj (neuronal marker) antibodies. Examples of neurons expressing
TNF-α are depicted with white arrowheads. Scale bar: 50 μm. (C) LPS treatment of enteric glial cell cultures did not induce TNF-α production
(between four and ten independent experiments). EGC, enteric glial cells; LMMP, longitudinal muscle/myenteric plexus; LPS, lipopolysaccharides;
rENSpc, rat enteric nervous system primary culture; S100β, S100 calcium binding protein beta; SEM, standard error of the mean; TNF-α, tumor
necrosis factor alpha; Tuj, βIII-tubulin.
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to an electrical stimulator (DualImpedance Research
Stimulator, Harvard Apparatus Ltd, Edenbridge, United
Kingdom). The electrical field stimulation (EFS) parame-
ters used were trains of constant current pulses (pulse
duration: 20 μs; amplitude: 8 V; frequency: 15 Hz) ap-
plied for seven hours, with reversal of electrode polarity
every 30 minutes, and supernatants and lysates were col-
lected after 24 hours for ELISA TNF-α measurements
and quantitative PCR (qPCR). Neuronal activation was
verified by analysis of c-Fos expression after seven hours
of EFS (Additional file 1). Putative neuronal damageinduced by EFS was also verified. Following seven hours
of EFS, no change in neuron-specific enolase (NSE) in
the culture medium or in protein gene product (PGP)
9.5 expression was observed as compared to control
(non-stimulated condition), suggesting that EFS did not
affect neuronal viability. Neuronal activity during the
seven hours was also measured using an essential neuro-
mediator, ATP.
Enteric glial cells
Primary cultures of human and adult rat EGCs were
obtained according to the procedure described by Soret
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colonic resections of patients with colorectal cancer (ac-
cording to the guidelines of the French Ethics Committee
for Research on Human and registered under the number
DC-2008-402). Adult rat EGC were obtained from entire
small intestines of Sprague-Dawley rats. After dissection
of rat or human segments, the remaining longitu-
dinal muscle-myenteric plexus (LMMP) was placed in
GentleMACS tubes C in a GentleMACS dissociator
(MiltenyiBiotec, Bergisch Gladbach, Germany) for enzy-
matic digestion (250 μl protease, 5 g/l−1; 250 μl collage-
nase, 20 g/l−1; 400 μl bovine serum albumin, 50 g/l−1;
Sigma-Aldrich) and mechanical dissociation in DMEM/
F12 medium (supplemented with 10% heat-inactivated
fetal calf serum, 100 IU/ml penicillin, 100 μg/ml strepto-
mycin, 1.1 μg/ml amphotericin B, 20 μg/ml gentamicin,
6 mM glutamine and 2.1 g/l NaHCO3; Life Technologies).
Following gentle agitation at 37?C, pellets were washed
and resuspended in DMEM/F12 complete medium. The
suspension was placed under a microscope and ganglia
were picked up using a pipette with a sterile tip and
seeded in 24-well plate coated with gelatin. After 48 hours,
the medium was entirely replaced and only EGC prolife-
rated to reach confluency after two to four weeks. The pri-
mary cultures of EGC from rat embryos (JUG2 cell line)
was obtained as described by Bach-Ngohou et al. [17] and
derived from ENS primary culture after trypsinization and
differential centrifugation. EGC were treated with LPS at a
concentration of 0.1 μg/ml for seven hours before collec-
ting supernatants.
Human tissue experiments
Colonic segments were pinned in a dissection dish con-
taining ice-cold, sterile oxygenated Krebs solution (Sigma-
Aldrich). Mucosae, submucosal and circular muscles were
carefully removed under a dissection microscope and the
remaining LMMP was placed in a 24-well plate containing
DMEM/F12 complete medium (supplemented as in EGC
primary culture procedure). The following day, the me-
dium was replaced with 1:1 DMEM-F12 containing 1%
N-2 supplement, and specimens were electrically sti-
mulated with the same equipment and parameters as for
rENSpc stimulation. After seven hours, supernatants and
lysates were collected and tissues were weighted to
normalize the ELISA analysis.
Immunofluorescence
After treatments, rENSpc were fixed in PBS containing 4%
paraformaldehyde at room temperature for 30 minutes.
Following pre-incubation in PBS containing 5% donkey
serum and 0.5% Triton? X-100 (Sigma-Aldrich) for 30 mi-
nutes, cells were incubated with the following primary
antibodies overnight at 4?C: rabbit anti-phospho-p44/p42
(P-ERK), rabbit anti-phospho-acetyl coenzyme A (CoA)carboxylase (P-ACC; 1:500; Cell Signaling Technology,
Beverly, Massachusetts, United States), goat anti-TLR2
(1:50; Santa Cruz Biotechnology, Dallas, Texas, United
States), and goat anti-TNF-α (1:200; Santa Cruz Bio-
technology). Anti-rabbit and anti-goat conjugated to
Cyanine3 (1:500; Jackson Immunoresearch, West Grove,
Pennsylvania, United States) were used as secondary
antibodies for one hour. In the following step, the cells
were labelled with primary antibodies for neuronal or glial
markers: mouse anti-Hu (1:200; Molecular Probes?, Life
Technologies), rabbit anti-PGP9.5 (1:1,000; Ultraclone
Limited, Tebu-bio, Le Perray-en-Yvelines, France), mouse
anti-Sox10 (1:500; R&D systems, Minneapolis, Minnesota,
United States), rabbit anti-S100b (1:1,000; DakoCytomation,
Glostrup, Denmark), mouse anti-S100b (1:1,000, Abcam,
Cambridge, United Kingdom), and mouse anti-β-tubulin
III (1:1,000; Sigma-Aldrich). After secondary antibodies
(FluoProbes? 488; 1:200; Interchim or Cyanine5; 1:200;
Jackson Immunoresearch), images were acquired with an
Olympus IX 50 fluorescence microscope coupled to a
digital camera (model DP71, Olympus), analyzed with Cell
B software (Soft Imaging System, Olympus), and trea-
ted with Image J software (National Institute of Health,
Bethesda, Maryland, United States).
Immunoblotting
ENS cells cultured for different times (as indicated),
with or without stimuli, LPS or agonists, were lysed
in RA1 (Nucleospin RNAII, Macherey-Nagel, D?ren,
Germany) to separate RNA and proteins. Proteins were
precipitated and pellets were resuspended in Phosphate-
buffered saline/tris (2-carboxyethyl)phosphine (PSB/TCEP)
(Macherey-Nagel). Samples were processed for elec-
trophoresis using NuPAGE ? MES SDS buffer kit (Life
Technologies) and separated on 4 to 12% Bis-Tris gels
(NuPAGE, Life Technologies). Proteins were transferred
to nitrocellulose membranes with the iBlot ? system
(Life Technologies). After blocking with Tris-buffered
saline (TBS), 0.1% Tween 20 and 5% nonfat dry milk for
one hour, blots were incubated overnight at 4?C with
primary antibodies diluted in TBS and 5% nonfat dry milk
for rabbit anti-phospho-Thr172-AMPK (P-AMPK), rabbit
anti-AMPK, rabbit anti-phospho-p44/p42 (P-ERK), rabbit
anti-p44/p42 and rabbit anti-phospho-ACC (1:500; Cell
Signaling Technology), and mouse anti-beta-actin (1:5000;
Sigma-Aldrich). Immunoblots were probed with the ap-
propriate horseradish peroxidase-conjugated secondary
antibodies (Life Technologies) and visualized by chemi-
luminescence (ECL Crescendo or Forte, Merk Millipore).
Quantitative analysis was performed using Image J soft-
ware. The value of phosphorylated and total protein im-
munoreactivity was normalized to the amount of β-actin
immunoreactivity and expressed as the fold increase rela-
tive to the control, taken as 1.
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According to the manufacturer ? s recommendations,
total RNA extraction from cells was performed with
Nucleospin RNAII kit (Macherey-Nagel) and 1 μg pu-
rified RNA was denatured and processed for reverse
transcription using Superscript II reverse transcrip-
tase (Life Technologies). PCR amplifications were
performed using the Absolute Blue SYBR green fluo-
rescein kit (Roche, Basel, Schweiz) run on a Rotor-Gene
(Qiagen, Venlo, The Netherlands). The following pri-
mers were used:
S6 number: [GenBank:NM_001010]. Forward primer: 5? -
CCAAGCTTATTCAGCGTCTTGTTACTCC-3? . Reverse
primer: 5 ? -CCCTCGAGTCCTTCATTCTCTTGGC-3 ? .
TNF-α number: [GenBank:NM_012675.3]. Forward pri-
mer: 5? -CTCATTCCTGCTCGTGGCGGG-3? . Reverse pri-
mer: 5? -TACGACGTGGGCTACGGGCTT-3? .TLR2 number:
[GenBank:NM_198769.2]. Forward primer: 5? -CAGATG
GCCAGAGGACTCA-3? . Reverse primer: 5? -AATGGCC
TTCCCTTGAGAG-3? .
Relative quantification of gene expression was deter-
mined using the standard curve method and endogenous
control ribosomal protein S6 mRNA. The ratios, TNF-α/
S6 or TLR2/S6, were compared with control experimen-
tal conditions normalized to 1.ELISA
The concentrations of TNF-α and IL-6 were determined
in rENSpc and human LMMP specimen culture superna-
tants by ELISA (BD OptEIA? ELISA Set, BD Biosciences,
Franklin Lakes, New Jersey, United States) according
to the manufacturer's instructions. Absorbance measure-
ments were performed at 450 nm on a spectrophoto-
metric enzyme-linked immunosorbent sandwich assay
(ELISA) plate reader (Varioskan ? , Thermo Scientific,
Waltham, Massachusetts, United States) using the
SkanIt software (Thermo Scientific). For human LMMP
specimens, the TNF-α concentration was expressed re-
lated to the weight of the specimen.Statistical analysis
Data resulted from independent experiments performed
in duplicate or triplicate. Statistical significance was
evaluated using GraphPad Prism software (GraphPad
Software Inc., La Jolla, California, United States). For
time- and dose-dependent experiments, a two-way
ANOVA test followed by a Bonferroni post-hoc test was
used. The time-dependent response to LPS in Western
blots was analyzed with a Kruskal-Wallis nonparametric
ANOVA test, followed by Dunn ? s post-hoc test. The dif-
ferences between groups were calculated by a two-tailed
Student ? s t-test for nonparametric and unpaired data, or
by Mann-Whitney U test.Results
Neurons of the enteric nervous system produce TNF-α in
response to lipopolysaccharide stimulation
To determine whether the ENS could respond to LPS by
producing proinflammatory cytokines, we measured
TNF-α concentrations in the supernatants of rENSpc
treated with different concentrations of LPS for two to
24 hours. We have verified that neurons of the rENSpc
expressed the TLR4 and were thereby able to respond to
LPS (Additional file 2). The TNF-α concentration was
significantly increased after eight hours of 1 μg/ml LPS
stimulation, and between 12 to 24 hours for LPS concen-
trations ranging from 0.01 to 1 μg/ml (Figure 1A). We
chose the intermediate LPS concentration (0.1 μg/ml) for
the rest of the study. Using immunocytochemistry, we fur-
ther aimed to identify the ENS cell type (neuronal or glial)
expressing TNF-α. In rENSpc, enteric neurons were orga-
nized in ganglia connected to each other by intergan-
glionic fiber strands as demonstrated by immunostaining
using βIII-tubulin (Tuj) antibody (Figure 1B). EGCs,
identified by S100β immunostaining, were also present in
enteric ganglia (Figure 1B). We showed that in rENSpc
treated with LPS for 24 hours, TNF-α immunoreactivity
was detected in the cytoplasm of Tuj-positive cells, but
not in S100β-positive cells (Figure 1B). To confirm that
EGC do not produce TNF-α, we measured TNF-α pro-
duction from human, adult and embryonic rat EGC in
response to treatment with LPS. None of these cells
responded to LPS treatment with an increase in TNF-α
production (Figure 1C). Our results show that enteric
neurons are the cells of the rENSpc producing TNF-α in
response to LPS stimulation.
Rat enteric nervous system activation inhibits the
lipopolysaccharide-induced increase in TNF-α transcript
and protein levels
To assess if ENS activity could regulate TNF-α production,
we measured LPS-induced TNF-α production in the su-
pernatants of rENSpc after EFS and in those not treated
with EFS. EFS had no significant effect on basal TNF-α
production. However, EFS significantly inhibited TNF-α
production induced by LPS in rENSpc (Figure 2A). qPCR
analysis indicated that EFS inhibited the increase in TNF-α
mRNA level observed after LPS (Figure 2B). These results
show that LPS induce an increase in TNF-α transcript and
protein levels, and that ENS activation reduces TNF-α
production.
ATP inhibits lipopolysaccharide-induced production of
TNF-α through P2X7 receptor activation
Various studies have demonstrated the anti-inflammatory
effects of adenosine receptor activation [18,19] and ATP is
a common intercellular messenger produced by enteric
neurons [20]. To determine their putative regulatory role
Figure 2 ENS activation in rat primary cultures inhibits the
LPS-induced increase in TNF-α transcript and protein levels.
(A) Evaluation of the impact of electrical field stimulation (EFS) on
TNF-α secretion was performed by ELISA in rENSpc treated (+) or
not (−) with LPS (0.1 μg/ml) (twelve independent experiments).
(B) TNF-α mRNA expression was measured in rENSpc by qPCR (twelve
independent experiments). (C) The effect of ATP (100 μM) and
involvement of P2X7 receptor on TNF-α secretion were measured by
ELISA in ENS cultures pretreated or not with BzATP (P2X7 agonist;
100 μM) or A439079 (P2X7 antagonist; 30 μM) (five independent
experiments). Values represent the mean ? SEM (Mann-Whitney U test;
*P <0.05 as compared with control without LPS; #P <0.05 LPS with
EFS, agonist or antagonist versus LPS alone; ? P <0.05 LPS with ATP
compared with LPS with ATP in presence of A438079). ATP, adenosine-
5'-triphosphate; BzATP, 2 ? (3 ? )-O-(4-benzoylbenzoyl) adenosine-5'-
triphosphate triethylammonium salt; CT, control; EFS, electrical field
stimulation; LPS, lipopolysaccharide; mRNA, messenger ribonucleic
acid; rENSpc, rat enteric nervous system primary culture; SEM,
standard error of the mean; TNF-α, tumor necrosis factor alpha.
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the potential role of ATP and purinergic receptor ac-
tivation. An increased extracellular ATP concentration
remarkably decreased the LPS-induced production of
TNF-α. The application of BzATP, a P2X7 agonist, in-
duced a similar reduction in TNF-α production, as did
ATP. The ATP effects were partially reversed by the selec-
tive P2X7 antagonist, A438079 (Figure 2C). These results
show that LPS-induced TNF-α production is reduced by
ATP stimulation of P2X7 receptors.
ERK and AMPK inhibition prevent lipopolysaccharide-
induced TNF-α upregulation
To decipher the signaling pathways responsible for LPS-
induced TNF-α synthesis by the ENS, and its mo-
dulation by EFS, we analyzed the possible implication of
the canonical extracellular signal-regulated kinase (ERK)
pathway, and also of the 5'-adenosine monophosphate-
activated protein kinase (AMPK) pathway. By Western
blot analysis using phospho-specific antibodies recog-
nizing the active form of the ERKs, we showed that
phosphorylation of ERKs was increased after two hours
of LPS stimulation, with no change in ERK expression
(Figure 3A). Activation of the AMPK pathway can be
measured by the phosphorylation of the Thr172 of the
AMPK itself, or by the phosphorylation of acetyl-CoA
carboxylase (ACC), an AMPK target, on its Ser19. Nei-
ther AMPK nor ACC phosphorylation changed signifi-
cantly over time, with or without LPS treatment (data
not shown). Immunocytochemical analyses revealed that
the immunoreactivity for phospho-ERK and phospho-
ACC concurred with Tuj and Hu (neuronal markers),
but not with S100β or Sox10 (glial markers) immunoreac-
tivity (Figure 3B). These data show that, while the AMPK
pathway was constitutively activated in neuronal cells,
ERKs were activated in neurons after LPS treatment.
Figure 3 (See legend on next page.)
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Figure 3 ERK and AMPK inhibition prevent LPS-induced increase in TNF-α transcript and protein levels. (A) ERK pathway activation in
rENSpc treated with LPS from two minutes to seven hours was measured by Western blotting using phospho-ERK antibodies (P-ERK). The relative
amount of P-ERK was determined by normalizing with β-actin (four to eight independent experiments). Values represent the mean ? SEM as
fold/mean t0 (one-way ANOVA test followed by Dunn? s post-hoc test; *P <0.05 as compared with t0 without LPS). (B) Localization of activated −
ERK and − AMPK in rENSpc treated for two hours with LPS was performed by immunocytochemistry using P-ERK or phospho-Acetyl-CoA Carboxylase
(P-ACC), with S100β and Sox10 (glial markers) or Hu and Tuj (βIII-tubulin, neuronal markers). Scale bar: 50 μm. Inserts show higher magnification images
(40x for P-ERK and 100x for P-ACC). ERK- and AMPK-dependent pathway contribution to TNFα production were assessed using MEK1/2 inhibitor (U0126;
10 μM) and AMPK inhibitor (C compound, CC; 10 μM) co-treatment on rENSpc treated (+) or not (−) with LPS for seven hours. (C) Quantification of
TNF-α mRNA by qPCR (six to 11 independent samples). (D) TNF-α secretion was assayed by ELISA with or without the presence of inhibitors (six
independent samples). The independence of the ERK and AMPK pathways was determined by Western blotting. (E) ERK phosphorylation was not
affected by CC and (F) ACC phosphorylation was not modified by U0126 (eight and three independent experiments, respectively). (Mann-Whitney
U test; *P <0.05 as compared with control without LPS; #P <0.05 as compared with LPS without inhibitor). (G) The EFS impact on ERK and AMPK
activation was measured on rENSpc treated (+) or not (−) with LPS and EFS for two hours by Western blotting using P-ERK and P-AMPK antibodies.
Immunoblots are representative of five independent experiments with similar results.
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inhibitors of the ERK or AMPK pathways, respectively,
significantly reduced TNF-αmRNA expression (Figure 3C)
and TNF-α production (Figure 3D). Interestingly, ERK
phosphorylation was not affected by compound C
(Figure 3E), and ACC-phosphorylation was not modified
by U0126 (Figure 3F), again suggesting the independence
of the two pathways. These results demonstrate that the
AMPK and ERK pathways participate independently in
LPS induction of TNF-α production by the ENS.
Electrical field stimulation inhibits AMPK and
lipopolysaccharide-induced ERK activation
To determine if EFS could inhibit TNF-α production by
modulating the ERK and AMPK pathways, we analyzed
ERK and AMPK activation in rENSpc treated, or not,
with LPS, in the presence or absence of EFS. EFS had no
significant effect on basal pathway activity but, com-
bined with LPS treatment, it significantly reduced the
phosphorylation of ERK and AMPK compared to the
LPS conditions (Figure 3G). This suggests that ENS
activation limits TNF-α production by inhibition of LPS-
induced ERK activation and decrease of AMPK activity.
Human enteric nervous system activation inhibits the
lipopolysaccharide-induced increase in TNF-α production
To assess if the induction of TNF-α production by LPS
and its regulation by EFS also occurs in human samples,
we measured LPS-induced TNF-α production in the
supernatants of human LMMP after, or not, EFS. EFS
had no significant effect on basal TNF-α production.
However, EFS significantly inhibited TNF-α production
induced by LPS in the LMMP (Figure 4A). The ap-
plication of BzATP, a P2X7 agonist, induced a similar re-
duction in TNF-α production (Figure 4B). Pretreatment
of LMMP with U0126 or compound C inhibitors of the
ERK or AMPK pathways, respectively, significantly re-
duced TNF-α production (Figure 4C). These results
show that in human LMMP as in rENSpc, LPS induces anincrease in TNF-α production that depends on AMPK
and ERK pathways, and that ENS activation reduces this
production by stimulation of the P2X7 receptors.
Rat enteric nervous system primary cultures upregulate
the neuronal expression of TLR2 in response to
lipopolysaccharide stimulation
To further investigate the ENS response to LPS, we mea-
sured, using qPCR, TLR2 mRNA expression in rENSpc.
TLR2 mRNA was detected in control conditions and LPS
treatment induced a strong increase in its expression
(Figure 5C). To determine if this regulation also occurred
at the protein level, and to identify the cells expressing
TLR2, we compared immunoreactivity for TLR2 with im-
munoreactivity for the neuronal marker Tuj or for the
glial marker S100β on rENSpc stimulated, or not, with
LPS. TLR2 immunoreactivity was detected slightly in our
control conditions but clearly appeared in Tuj-positive
cells, and rarely in S100β-positive cells, when rENSpc
were treated with LPS (Figure 5A). To confirm that TLR2
expression is mainly neuronal, we have analyzed TLR2 im-
munoreactivity in human EGC. The glial marker S100β
staining of cultures of human EGC always present highly
positive cells and low positive cells. Only the highly
S100β-positive EGC also expressed the TLR2 (Figure 5B),
but no changes were observed after LPS stimulation. All
together these data show that mainly enteric neurons
express the TLR2 and respond to LPS through TLR2
upregulation.
Lipopolysaccharide-induced TNF-α production
participates in TLR2 upregulation and can be prevented
by electrical field stimulation activation of the enteric
nervous system
To determine if TNF-α production induced by LPS
could be involved in the TLR2 upregulation observed in
enteric neurons in response to LPS, we measured TLR2
mRNA in rENSpc stimulated by LPS in the absence or
presence of TNF-α-neutralizing antibodies. Anti-TNF-α
Figure 4 ENS activation in human LMMP inhibits the LPS-
induced TNF-α production. (A) The impact of electrical field
stimulation (EFS) on TNF-α secretion by the human LMMP treated
(+) or not (−) with LPS (0.1 μg/ml) was performed by ELISA (four
independent experiments each performed in triplicate; CT means
control). (B) The involvement of P2X7 receptor on TNF-α secretion
were measured by ELISA in human LMMP pretreated, or not, with BzATP
(P2X7 agonist; 100 μM) before LPS stimulation (three independent
experiments each performed in triplicate; CT means control). (C) ERK-
and AMPK-dependent pathway contribution to TNFα production
induced by LPS were assessed using MEK1/2 inhibitor (U0126; 10 μM)
and AMPK inhibitor (C compound, CC; 10 μM) co-treatment on human
LMMP treated, or not, with LPS for seven hours (three independent
experiments each performed in triplicate; CT means control). Values
represent the mean ? SEM (Mann-Whitney U test; * P <0.05 as
compared with control without LPS; #P <0.05 LPS with EFS, agonist
versus LPS alone). AMPK, 5 ? -AMP-activated protein kinase; BzATP,
2? (3? )-O-(4-benzoylbenzoyl) adenosine-5'-triphosphate triethylammonium
salt; CT, control; CC, C compound; CT, control; EFS, electrical field
stimulation; ERK, extracellular signal-regulated kinase; LMMP, longitudinal
muscle/myenteric plexus; LPS, lipopolysaccharide; MEK1/2, mitogen-
activated protein kinase kinase 1/2; SEM, standard error of the mean;
TNF-α, tumor necrosis factor alpha.
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TLR2 mRNA induced by LPS (Figure 5D). In the same
manner, EFS stimulation of the rENSpc significantly
reduced the TLR2 mRNA expression induced by LPS
(Figure 5E). These data show that TNF-α production in-
duced by LPS upregulated the TLR2 receptor expression
and depends on ENS activity.TLR2 activation induces TNF-α production
TLR2, as well as TLR4, activation in different cell types
can induce TNF-α production [21]. To assess the in-
volvement of TLR2 in the ENS response to LPS, we
measured TNF-α production in rENSpc stimulated with
the TLR1/2 agonist, Pam3CSK4. Pam3CSK4 induced a
significant increase in TNF-α production that could be
further increased after the addition of LPS (Figure 5F).
These results suggest that TLR2 activation can induce
TNF-α production by enteric neurons.Interleukin-6 production is potentiated by enteric
nervous system activation
An additional functional consequence of TNF-α regula-
tion by ENS activity could be the regulation of other cyto-
kines, such as interleukin-6 (IL-6). To address this issue,
we measured IL-6 production by rENSpc treated with LPS
in the absence or presence of TNF-α-neutralizing anti-
bodies. Like TNF-α, IL-6 production was increased by
LPS, but this was delayed in time compared to the TNF-α
response (data not shown). TNF-α-neutralizing antibodies
had no effect on basal IL-6 production but, surprisingly,
significantly increased that induced by LPS (Figure 6A).
EFS stimulation of the ENS increased the IL-6 production
Figure 5 (See legend on next page.)
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Figure 5 LPS-induced TNF-α production leads to TLR2 upregulation and TLR2 contributes to TNFα production. (A) Localization of TLR2
on neuronal or glial cells of the rENSpc was analyzed by immunocytochemistry using anti-TLR2, ? Tuj (β-tubulin III) and ? S100β antibodies on
cultures treated for seven hours with LPS (0.1 μg/ml), or not. Scale bar: 50 μm. (B) Expression of TLR2 was also observed in human EGC cultures
by immunocytochemistry using anti-TLR2 and ? S100β antibodies on cultures treated for seven hours with LPS (0.1 μg/ml), or not. (C) Relative
expression of TLR2 mRNA in rENSpc treated (+), or not (−), with LPS for seven hours (15 independent samples). Values represent the mean ? SEM
of TLR2 mRNA quantification against RPS6 (Mann-Whitney U test; *P <0.05 as compared with control without LPS). (D) Quantification of TLR2
mRNA in rENSpc treated (+), or not (−), with LPS (0.1 μg/ml) in the presence of, or not, anti-TNF-α (1 μg/ml and 10 μg/ml), was performed by
RT-qPCR (five independent samples) (Mann-Whitney U test; *P <0.05 as compared with control without LPS; #P <0.05 as compared with LPS
treatment without anti-TNFα). (E) TLR2 mRNA expression in rENSpc treated (+), or not (−), with LPS in the presence of, or not, EFS stimulation
(11 to 16 independent samples). TLR2 mRNA quantification relative to S6 was expressed as induction fold to the control mean (Mann-Whitney
U test; *P <0.05 as compared with control without LPS; #P <0.05 as compared with LPS treatment without EFS). (F) ENS cultures were treated (+),
or not (−), with LPS (0.1 μg/ml) and Pam3CSK4 (TLR1/2 agonist; 0.1 μg/ml). Values represent the mean ? SEM of eight independent experiments
(Mann-Whitney U test; *P <0.05 as compared with control without LPS; ? P <0.05 as compared with Pam3CSK4 without LPS).
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TNF-α downregulation, can potentiate IL-6 production.
Discussion
In this study, we showed that stimulation of human or
rat ENS by LPS induces neuronal production of TNF-α,
which is inhibited by neuronal activity. This regulation
partially occurs through the inhibition of the ERK and
AMPK neuronal pathways activated by LPS, and can be
reproduced by ATP via P2X7 receptors. Furthermore,
neuronal activation leads to a TNF-α-dependent inhi-
bition, LPS-induced neuronal TLR2 downregulation, and
IL-6 production.
TNF-α production is one of the common inflamma-
tory responses of the gut to LPS endotoxin. An increase
in plasma TNF-α level occurs in an animals as early as
90 minutes after an intraperitoneal injection of LPS [22].
In addition to this acute TNF-α production, an elevated
level of circulating TNF-α can be measured during chro-
nic inflammation, such as IBD [23]. In this context, our
work addressed the question of identifying the ENS as
TNF-α-producing cells, among other known cells of the
gut. Indeed, in the gut, TNF-α is produced by activatedFigure 6 ENS activation potentiates IL-6 production due to downregu
presence, or not, of anti-TNF-α (1 μg/ml and 10 μg/ml) was measured in an
EFS stimulation on IL-6 production by ENS cultures treated (+) with LPS (0.1
represent the mean ? SEM (Mann-Whitney U test; * P <0.05 as compared w
EFS, electrical field stimulation; LPS, lipopolysaccharide; rENSpc, rat enteric n
factor alpha.macrophages, CD4+ lymphocytes, natural killer [24] and
dendritic cells. In addition, nonimmune cells such as epi-
thelial cells, endothelial cells, smooth muscle cells, vascu-
lar smooth muscle cells, fibroblasts and cardiac myocytes
have also been shown to produce TNF-α [25,26]. Our
work showed that enteric neurons in primary culture pro-
duce TNF-α in response to LPS stimulation. In contrast,
we were unable to detect any TNF-α production, with or
without LPS, in EGCs (from rENSpc, or from rat or hu-
man EGCs). Besides producing TNF-α, enteric neurons
have also previously been shown to produce other cyto-
kines and chemokines, such as IL-8 [27]. Production of
TNF-α has also been shown in the CNS, by neurons
[28,29] and also, in contrast to the ENS, by astrocytes
[19,30]. Altogether, our study suggests that enteric neu-
rons could, as resident cells, relay a first inflammatory re-
action to LPS by producing TNF-α.
It is well known that the synthesis of biologically active
TNF-α is regulated at several different levels and that
mitogen-activated protein kinase (MAPK) pathways are
critical for its production, as well as for that of several
other proinflammatory cytokines [31]. LPS can signal
through all three p38, c-Jun N-terminal kinase (JNK)lation of TNF-α. (A) LPS-induced IL-6 production in rENSpc in the
ELISA assay (five to seven independent samples). (B) The impact of
μg/ml) or without (−) (four to eight independent experiments). Values
ith control without LPS; #P <0.05 as compared with LPS treatment).
ervous system; SEM, standard error of the mean; TNF-α, tumor necrosis
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stream effectors to regulate TNF-α transcription [34], as
well as TNF-α translation [35,36]. We observed that
ERKs were activated in enteric neurons after LPS chal-
lenge, and that ERK pathway inhibition significantly, but
only partially, inhibited TNF-α production and transcrip-
tion. It was more surprising to observe the basal activation
of the AMPK pathway in enteric neurons and the drastic
inhibition of LPS-induced TNF-α transcription and pro-
duction by the AMPK inhibitor, C compound. Indeed,
several studies, using various inflammatory stimuli, have
shown that the energy-sensing enzyme AMPK has anti-
inflammatory actions thought to be largely mediated by
negative regulation of the nuclear factor-kappa B (NF-κB)
pathway [37-41]. However, some evidence emphasizes the
dual effect of C compound on the inflammatory response,
which upregulated the release of TNF-α production in
non-stimulated microglia, but downregulated TNF-α re-
lease in LPS-stimulated microglia [42]. This complex
regulation is consistent with the inhibition of ERK and
AMPK phosphorylation by ENS activation.
In a more general consideration, ERK is known to be ac-
tivated in response to stimuli linked to neuronal activity
[43]. However, it is also well known that the activation of
MAPK is transient [43,44] and hardly ever sustained in
physiological conditions, due to desensitizing or negative
feedback processes. We could assume that ENS activation
precociously activates ERK pathways that might not be
further impacted by LPS stimulation. We also observed
that EFS effects on LPS-induced TNF-α production can
be reproduced with ATP (Figure 2D), but not with ace-
tylcholine, serotonin or vasoactive intestinal polypeptide
(unpublished results). The ATP-induced inhibition of
TNF-α production was reproduced by activation of the
purinergic receptor, P2X7, and blocked in part by a P2X7
antagonist. Various studies have recently reported a wide
range of actions of P2X7 in enteric neurons. First, P2X7
expression has been reported to be widely expressed in
enteric neurons [45,46]. Activation of P2X7 has been
shown to increase neuronal excitability [45], as well as
being responsible for neuronal death induced by inflam-
mation [47]. Here, we observed that activation of the
P2X7 receptor could limit TNF-α production in enteric
neurons.
TNF-α can have various effects on different cell types,
such as immune cells, intestinal epithelial cells or even
muscle cells during intestinal inflammation [48-52]. Our
study suggests that production of TNF-α by enteric neu-
rons can modulate neuronal functions in an autocrine
manner, as demonstrated by the TNF-α-dependent in-
crease in neuronal TLR2 expression. TNF-α has also been
reported to have multiple other effects on enteric neurons.
For instance, TNF-α has been shown to inhibit norepin-
ephrine release from the rat myenteric plexus [53], tomodulate neuronal excitability [54] and even have neu-
roprotective effects [55]. TNF-α production by enteric
neurons could also induce enteric glial reactivity [56]. In
addition, we have shown that TNF-α limits LPS-induced
IL-6 production, which is, however, amplified when the
ENS is activated. This pleiotropic cytokine has a central
role in generating acute-phase responses, inflammation
and lymphocyte differentiation. Concerning the ENS, IL-6
increases neuronal excitability [57-59], and can participate
in gastrointestinal dysfunction associated with intestinal
inflammation or irritable bowel syndrome. In addition,
IL-6 can also reduce enteric neuronal survival [60]. In our
study, the cellular origin of IL-6 was not investigated but
may involve both EGCs and intestinal smooth muscle
cells, both of which respond to TNF-α stimulation by IL-6
production [61,62].
We also demonstrated that LPS-induced TNF-α pro-
duction by enteric neurons induced the neuronal expres-
sion of TLR2. TLR2 expression induced by LPS has
already been described in endothelial cells [63], and our
work extends this regulation to neuronal cells, and shows
that this regulation occurs through TNF-α production.
TLR2 is a TLR of particular interest because it mediates
reaction to inflammation [64], could have nonimmune
functions and effects opposite those mediated by TLR4
[65] and its expression is induced in the intestines of pa-
tients with IBD [66]. The LPS-induced increase in TLR-2
expression in enteric neurons could participate in a pro-
tective response to inflammatory or infectious challenges,
as recent data have reported that genetic deficiency of
TLR2 induces anomalies in the structure, neurochemical
coding and function of ENS. This is in part due to glial
cell-derived neurotrophic factor (GDNF) production [14],
which has been shown to have central neuroprotective
and neuromodulatory effects in the ENS [67,68].
Conclusions
Although in vivo data are lacking to make conclusions
about the impact of ENS activity on the intestinal re-
sponse to LPS, our study is the first demonstration that
the ENS can produce TNF-α, that its activation inhibits
TNF-α production and TLR2 expression, and also po-
tentiates IL-6 production. This study thus defines the
ENS as a potent player in neuroimmune inflammation.
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